Losses and mutations in these genes have been linked to primary (63) and acquired resistance to PD-1 blockade in melanoma (64), suggesting that melanoma cells become insensitive to the antiproliferative effects of IFNγ (via JAK1/2 alterations) or lose antigen presentation (via B2M alterations). The gene discussed is IFNG; the disease is melanoma.